Collagen alpha-1(XIII) chain (COL13A1) (COL13A1)

Collagen alpha-1(XIII) chain (COL13A1) is a type II transmembrane protein belonging to the Membrane-Associated Collagens with Interrupted Triple helices (MACIT) family [UniProt Q12930]. It is primarily localized at the neuromuscular junction (NMJ), where its large ectodomain is proteolytically shed from the cell surface by furin-like proprotein convertases to integrate into the synaptic extracellular matrix [PubMed: 28973925]. This shed ectodomain is crucial for the structural maturation and functional stabilization of the NMJ, interacting with key proteins such as MuSK and perlecan to facilitate acetylcholine receptor clustering [PubMed: 26524469]. Mutations in the COL13A1 gene lead to Congenital Myasthenic Syndrome type 19 (CMS19), a severe neuromuscular disorder characterized by early-onset muscle weakness and life-threatening respiratory crises [OMIM: 600570]. While there are currently no FDA-approved drugs that directly bind to Collagen XIII, beta-2 adrenergic agonists like salbutamol and ephedrine are used as standard-of-care to stabilize the synapse and improve motor function in affected patients [PubMed: 26524469]. Research is actively exploring the use of recombinant Collagen XIII ectodomain as a potential replacement therapy to restore synaptic integrity in CMS19 [PubMed: 28973925].

Other names

Collagen type XIIICOL13A1MACIT collagenCollagen XIII ectodomain

Beta-2 adrenergic agonists are utilized to stabilize the neuromuscular junction and enhance synaptic transmission in patients with Collagen XIII deficiency, although they do not directly bind to the protein itself [PubMed: 26524469].